Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

Julio E. Ayala, Deanna P. Bracy, Freyja D. James, Melissa A. Burmeister, David H. Wasserman, and Daniel J. Drucker

Department of Molecular Physiology and Biophysics (J.E.A., D.P.B., F.D.J., D.H.W.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232; Department of Medicine (D.J.D.), The Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada M5G 1X5; and Metabolic Signaling and Disease Program (J.E.A., M.A.B.), Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827

Glucagon-like peptide-1 augments nutrient-stimulated insulin secretion. Chow-fed mice lacking the glucagon-like peptide-1 receptor (Glp1r) exhibit enhanced insulin-stimulated muscle glucose uptake but impaired suppression of endogenous glucose appearance (endoRa). This proposes a novel role for the Glp1r to regulate the balance of glucose disposal in muscle and liver by modulating insulin action. Whether this is maintained in an insulin-resistant state is unknown. The present studies tested the hypothesis that disruption of Glp1r expression overcomes high-fat (HF) diet-induced muscle insulin resistance and exacerbates HF diet-induced hepatic insulin resistance. Mice with a functional disruption of the Glp1r (Glp1r+/−/−) were compared with wild-type littermates (Glp1r+/+++) after 12 wk on a regular chow diet or a HF diet. Arterial and venous catheters were implanted for sampling and infusions. Hyperinsulinemic-euglycemic clamps were performed on weight-matched male mice. [3-3H]glucose was used to determine glucose turnover, and 2[14C]deoxyglucose was used to measure the glucose metabolic index, an indicator of glucose uptake. Glp1r+/−/− mice exhibited increased glucose disappearance and muscle glucose metabolic index on either diet. This was associated with enhanced activation of muscle Akt and AMP-activated protein kinase and reduced muscle triglycerides in HF-fed Glp1r+/−/− mice. Chow-fed Glp1r+/−/− mice exhibited impaired suppression of endoRa and hepatic insulin signaling. In contrast, HF-fed Glp1r+/−/− mice exhibited improved suppression of endoRa and hepatic Akt activation. This was associated with decreased hepatic triglycerides and impaired activation of sterol regulatory element-binding protein-1. These results show that mice lacking the Glp1r are protected from HF diet-induced muscle and hepatic insulin resistance independent of effects on total fat mass. (Endocrinology 151: 0000–0000, 2010)

Glucagon-like peptide-1 (Glp1) and glucose-dependent insulinotropic polypeptide (Gip) are gut-derived peptides that enhance the secretion of insulin after nutrient intake. This incretin effect is mediated via activation of distinct receptors for Glp1 (Glp1r) and Gip (Gipr) expressed in pancreatic β-cells. The Glp1r and Gipr are also expressed in lungs, kidneys, heart, adipose tissue, and the central and peripheral nervous systems (1–4). Glp1, but not Gip, also inhibits glucagon secretion and delays gastric emptying (5–8), thereby diminishing glucose excursions after a meal.

Using the hyperinsulinemic-euglycemic clamp, or insulin clamp, we have demonstrated that the Glp1r and the
Glp1r also regulate insulin action. Double-incretin receptor knockout (DIRKO) mice, which lack expression of the Glp1r and the Gipr, exhibit enhanced whole-body insulin action (9). This was observed in mice fed a chow diet or a high-fat (HF) diet, the latter used to precipitate insulin resistance (10–12). DIRKO mice are also protected from HF diet-induced obesity (9). This is due, at least in part, to the loss of Gipr expression, which has been shown to reduce weight gain and fat mass in genetic, dietary, and aging models of obesity (13–17). Thus, the lack of Glp1r action in DIRKO mice is protective against HF diet-induced obesity, resulting in enhanced insulin action.

We recently showed that the loss of Glp1r expression also contributes to the enhanced insulin action observed in chow-fed DIRKO mice (18). Under euglycemic conditions, insulin-stimulated muscle glucose uptake (MGU) is enhanced in chow-fed Glp1r knockout (Glp1r<sup>−/−</sup>) mice. In light of this finding, it is paradoxical that suppression of endogenous glucose appearance (endoRa) by insulin is impaired in Glp1r<sup>−/−</sup> mice (18). This suggests a role for the Glp1r to regulate the balance of glucose disposal between the liver and muscle by modulating insulin action in these tissues.

Whether the Glp1r plays a role in regulating insulin action within the context of an insulin-resistant state is not known. Chronic (4 wk) inhibition of the Glp1r expressed in the brain via intracerebroventricular (icv) infusion of the Glp1r antagonist exendin 9-39 reduces fasting insulin and glucose and improves ip glucose tolerance in mice fed a carbohydrate-free HF diet (19). However, the impact of this Glp1r blockade on hepatic and muscle insulin action was not addressed. In the present studies, the hypothesis that disruption of Glp1r expression overcomes the muscle insulin resistance associated with HF feeding was tested. We further hypothesized that disruption of Glp1r expression would further exacerbate the impaired hepatic insulin action associated with HF feeding.

**Materials and Methods**

**Mouse maintenance and genotyping**

All procedures performed were approved by the Vanderbilt University Animal Care and Use Committee. At 3 wk of age, wild-type (Glp1r<sup>+/+</sup>) and Glp1r knockout (Glp1r<sup>−/−</sup>) littermates on a C57BL/6 background were separated by sex and placed on either a chow diet (Purina 5001; Purina Mills, St. Louis, MO) composed of 13, 58, and 28 kcal/g of fat, carbohydrate, and protein, respectively, or a HF diet (no. F3282; BioServ, Frenchtown, NJ) composed of 60, 24 and 16 kcal/g of fat, carbohydrate and protein, respectively. Genotyping was performed by PCR on genomic DNA obtained from tail biopsies. All experiments were performed on mice at about 4 months of age. Lean mass and fat mass were determined on 5 h-fasted mice using a mq10 NMR analyzer (Bruker Optics, Billerica, MA). Mice were maintained on a standard light-dark cycle (0600–1800 h light).

**Surgical procedures**

Only male mice were used for studies. Catheters were implanted in the left common carotid artery and right jugular vein for sampling and infusions, respectively, as previously described (12, 20, 21), except that surgeries were performed under inhaled isoflurane anesthesia (VetEquip, Pleasanton, CA). Animals were individually housed after surgery and allowed to recover for 5–7 d, during which time body weight was recorded daily. Mice that did not return to within 15% of presurgery weight or lost catheter patency were excluded from insulin clamp studies. Across both genotypes and diets, approximately 35% of mice initially selected for the studies did not undergo the clamp procedure due to these exclusion criteria or loss during surgery.

**Hyperinsulinemic-euglycemic clamps**

After 5 d of recovery, insulin clamps were performed on 5 h-fasted mice (9, 12, 18, 20). A 5-μCi bolus of [3-3H]glucose was given at t = −90 min before insulin infusion, followed by a 0.05-μCi·min<sup>−1</sup> infusion for 90 min. Blood samples were obtained via the arterial catheter (9, 12, 18, 20). Basal glucose-specific activity was determined from blood samples at t = −15 and −5 min. Fasting glucagon levels were determined from blood samples taken at t = −15 min. Fasting insulin and non-esterified fatty acid (NEFA) levels were determined from blood samples taken at t = −5 min. The clamp was begun at t = 0 min with a continuous infusion of human insulin (4 mU·kg<sup>−1</sup>·min<sup>−1</sup>, Humulin R; Eli Lilly, Indianapolis, IN). The [3-3H]glucose infusion was increased to 0.15 μCi·min<sup>−1</sup> for the remainder of the experiment. Euglycemia (~8.5 mmol·liter<sup>−1</sup>) was maintained by measuring blood glucose every 10 min (~1 μl of blood per sample) starting at t = 0 min and infusing 50% dextrose as necessary. Mice received saline-washed erythrocytes from donors beginning at t = 0 min and continuously throughout the clamp at a rate of 5.5 μl·min<sup>−1</sup> to prevent a fall of greater than 5% hematocrit. A 12-μCi bolus of 2<sup>14</sup>Cdeoxyglucose ([2<sup>14</sup>C]DG) was given at t = 120 min. Blood samples were taken every 10 min from t = 80 to 135 min (50 μl at every time point except at t = 120 min when 240 μl was taken) and processed to determine plasma [3-3H]glucose and [2<sup>14</sup>C]DG. Clamp insulin, NEFAs, and glucagon levels were determined at t = 120 min. At t = 135 min, mice were anesthetized with sodium pentobarbital. The gastrocnemius, superficial vastus lateralis, liver, diaphragm, heart, and brain were excised, immediately frozen, and stored at −80 °C until analyzed.

**Processing of plasma and tissue samples**

Plasma insulin was determined by ELISA (Millipore, Bedford, MA). NEFAs were measured spectrophotometrically by an enzymatic colorimetric assay (Wako NEFA HR(2) kit; Wako Chemicals, Richmond, VA). Plasma glucagon levels were determined by RIA by the Vanderbilt-National Institutes of Health Mouse Metabolic Phenotyping Center Hormone Assay and Analytical Resources Core. Plasma [3-3H]glucose and [2<sup>14</sup>C]DG were determined from deproteinized samples as previously described (9, 12). Tissue [2<sup>14</sup>C]DG-6-phosphate ([2<sup>14</sup>C]DGDP) radioactivity was determined as previously described (9, 12). Briefly, tissues were homogenized in 0.5% perchloric acid and homogenates were centrifuged and neutralized with KOH. One aliquot was counted directly to determine [2<sup>14</sup>C]DG and
Protein immunoblot

For whole-cell extracts, liver and muscle tissue (40–80 mg) was homogenized in 10 μl mg⁻¹ tissue extraction buffer (30 mM Tris; 1 mM EDTA; 1 mM EGTA; 10% glycerol; 1% Triton X-100, pH 7.5) supplemented with protease (Pierce, Rockford, IL) and phosphatase (Sigma, St. Louis, MO) inhibitor cocktails. Homogenates were centrifuged (20 min, 4500 × g, 4°C), pellets were discarded, and supernatants were retained for protein determination. Liver nuclear extracts were obtained using a nuclear extract isolation kit (Pierce) according to the manufacturer’s instructions. Protein content was determined using a bicinechonic acid protein assay kit (Bio-Rad Laboratories, Hercules, CA). Whole-cell (20–100 μg) and nuclear (20 μg) extracts were separated on 10% Bis-Tris SDS-PAGE gels (Invitrogen, Carlsbad, CA), followed by electrophoretic transfer to polyvinyl difluoride membranes. Primary antibodies were incubated with the membranes overnight at 4°C. Secondary antibodies were incubated at room temperature for 1 h. Imaging and densitometry were performed using the Odyssey imaging system (LI-COR, Lincoln, NE). Antibodies for Akt, phosphorylated Akt (Ser473), AMP-activated protein kinase (AMPK), and phosphorylated AMPK (Thr172) were from Cell Signaling (Beverly, MA). Antibody for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam. Antibodies for the nuclear form of sterol regulatory element-binding protein (SREBP)-1 and YY1 were a generous gift from Dr. T. Osborne (Sanford-Burnham Medical Research Institute).

Calculations

Whole-body glucose appearance and disappearance (Rd) were determined using Steele non-steady-state equations (23, 24). The endoRd was determined by subtracting the glucose infusion rate (GIR) from total glucose appearance. Glucose metabolic index (Rm) was calculated as previously described (25, 26) using the following equation: Rm = (2[14C]DGPtissue/AUC 2[14C]DGPplasma) * [arterial glucose], where 2[14C]DGPtissue is the 2[14C]DGP radioactivity in the tissue (in disintegrations per minute per gram), AUC 2[14C]DGPplasma is the area under the plasma 2[14C]DGP disappearance curve (in disintegrations per minute per milliliter), and arterial glucose is the average arterial plasma glucose (in millimoles per liter) from t = 2 to 35 min after the bolus of 2[14C]DGP.

Statistical analysis

Data are presented as mean ± SEM. Differences between groups were determined by one-way ANOVA followed by Tukey’s post hoc tests or two-tailed t test as appropriate. The significance level was P < 0.05.
accharacteristics are shown in Table 2. There were no significant differences in body weight between genotypes within each diet regimen (Table 2). Chow-fed Glp1r−/− mice exhibited mild fasting hyperglycemia compared with Glp1r+/+ mice, even as fasting insulin levels were equal. Plasma glucagon levels were insignificantly higher in Glp1r−/− mice on either diet (Table 2). The HF diet-induced increase in fasting glucose observed in Glp1r+/+ mice was not present in Glp1r−/− mice. HF feeding also resulted in a greater increase in fasting insulin levels in Glp1r+/+ mice than in Glp1r−/− mice. There were no differences in fasting NEFA levels between genotypes within each diet group. Fasting NEFA levels were insignificantly lower in HF-fed Glp1r−/− mice compared with HF-fed Glp1r+/+ mice, even though insulin levels were lower in the former (Table 2).

Arterial glucose was clamped at similar levels (~8.5 mmol·liter⁻¹) in all groups during the insulin clamps (Fig. 2, A and B, and Table 2). The GIR necessary to maintain euglycemia was not significantly different between chow-fed Glp1r+/+ and Glp1r−/− mice (Fig. 2C and Table 2). Contrasting this, the GIR was significantly higher in HF-fed Glp1r−/− mice compared with HF-fed Glp1r+/+ mice (Fig. 2D and Table 2). Clamp insulin levels were equal between genotypes and were significantly higher in HF-fed mice compared with chow-fed mice (Table 2). Clamp glucagon levels were not different between genotypes (Table 2). NEFA levels were suppressed by insulin in all groups except for HF-fed Glp1r+/+ mice (Table 2).

Basal endoRa (Fig. 3A) and Rd (Fig. 3B) were not different between genotypes or diets. There was a tendency for an impaired suppression of endoRa by insulin in chow-fed Glp1r−/− mice compared with Glp1r+/+ mice (P = 0.06). Contrasting this, insulin-mediated suppression of endoRa was significantly enhanced in HF-fed Glp1r−/− mice compared with Glp1r+/+ mice (Fig. 3A). Stimulation of Rq by insulin was significantly enhanced in Glp1r−/− mice, regardless of diet (Fig. 3B). Hepatic glycogen levels at the end of the insulin clamps were significantly lower in

<table>
<thead>
<tr>
<th>n</th>
<th>Weight (g)</th>
<th>Lean mass (g)</th>
<th>Fat mass (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glp1r+/+ chow</td>
<td>12</td>
<td>26.1 ± 0.5</td>
<td>20.1 ± 0.4</td>
</tr>
<tr>
<td>Glp1r−/− chow</td>
<td>13</td>
<td>26.6 ± 0.9</td>
<td>20.1 ± 0.6</td>
</tr>
<tr>
<td>Glp1r+/+ HF</td>
<td>14</td>
<td>38.8 ± 1.8a</td>
<td>22.6 ± 0.9a</td>
</tr>
<tr>
<td>Glp1r−/− HF</td>
<td>15</td>
<td>38.0 ± 1.2a</td>
<td>21.8 ± 0.4a</td>
</tr>
</tbody>
</table>

Weight, lean mass, and fat mass are shown for male mice of both genotypes after 12 wk of either chow or HF feeding. Measurements are in 5-h-fasted mice at 4 months of age. Results are shown as mean ± SEM.

a P < 0.05 vs. chow, same genotype.

### TABLE 2. Basal (5 h fasted) and insulin clamp characteristics in male mice

<table>
<thead>
<tr>
<th>n</th>
<th>Weight (g)</th>
<th>Arterial glucose (mmol·liter⁻¹)</th>
<th>Insulin clamp (pmol·liter⁻¹)</th>
<th>NEFA (mEq·liter⁻¹)</th>
<th>Glucagon (pg·ml⁻¹)</th>
<th>Hematocrit (%)</th>
<th>GIR (mmol·kg⁻¹·min⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glp1r+/+ chow</td>
<td>8</td>
<td>26.9 ± 0.7</td>
<td>7.9 ± 0.3</td>
<td>8.5 ± 0.3</td>
<td>0.70 ± 0.05</td>
<td>38</td>
<td>0.18 ± 0.01</td>
</tr>
<tr>
<td>Glp1r−/− chow</td>
<td>8</td>
<td>26.6 ± 0.5</td>
<td>9.2 ± 0.2a</td>
<td>9.0 ± 0.2</td>
<td>0.65 ± 0.06</td>
<td>46</td>
<td>0.22 ± 0.02</td>
</tr>
<tr>
<td>Glp1r+/+ HF</td>
<td>9</td>
<td>36.9 ± 1.6a</td>
<td>9.2 ± 0.5a</td>
<td>8.6 ± 0.1</td>
<td>1.45 ± 0.19a</td>
<td>41</td>
<td>0.11 ± 0.01a</td>
</tr>
<tr>
<td>Glp1r−/− HF</td>
<td>10</td>
<td>35.6 ± 1.6a</td>
<td>8.5 ± 0.6</td>
<td>8.6 ± 0.2</td>
<td>1.16 ± 0.16a</td>
<td>49</td>
<td>0.20 ± 0.02b</td>
</tr>
</tbody>
</table>

Basal glucose levels are from samples obtained at t = −15 and −5 min prior to the insulin clamp. Basal insulin and NEFA are from plasma samples obtained at t = −5 min prior to the insulin clamp. Basal glucagon is from plasma samples obtained at t = −15 min prior to the insulin clamp. Hematocrit readings were taken after taking blood samples at t = −5 min and at t = 120 min of the insulin clamp. GIR and clamp arterial glucose represent average values over t = 80–120 min of the insulin clamp. Clamp insulin, NEFA, and glucagon are from plasma samples obtained at t = 120 min of the insulin clamp.

a P < 0.05 vs. chow, same genotype.

b P < 0.05 vs. Glp1r+/+, same diet.
chow-fed Glp1r$^{-/-}$ mice. There was a tendency ($P = 0.06$) for hepatic glycogen levels to be lower in HF-fed Glp1r$^{-/-}$ mice (Fig. 3C). Regardless of diet, muscle glycogen levels were higher in Glp1r$^{-/-}$ mice (Fig. 3D).

**Insulin-stimulated muscle glucose uptake is enhanced in chow-fed and HF-fed Glp1r$^{-/-}$ mice**

As shown in Fig. 4, A and B, Rg in hindlimb skeletal muscles was significantly higher in chow-fed Glp1r$^{-/-}$ mice. Rg in the diaphragm (Fig. 4C) and heart (Fig. 4D) was not different between genotypes. HF diet-induced muscle insulin resistance was observed in Glp1r$^{+/+}$ mice as Rg was significantly lower in all muscles examined compared with chow-fed mice (Fig. 4). Whereas HF-fed Glp1r$^{-/-}$ mice exhibited muscle insulin resistance relative to their chow-fed counterparts, skeletal muscle Rg was higher compared with HF-fed Glp1r$^{+/+}$ mice (Fig. 4, A and B). Taken together, results from the insulin clamp studies demonstrate that disruption of Glp1r expression enhances muscle insulin action in chow-fed mice and both muscle and hepatic insulin action in HF-fed mice.

**Muscle and liver Akt activation are enhanced in HF-fed Glp1r$^{-/-}$ mice**

Activation of muscle Akt was assessed to determine whether increased muscle Rg and glycogen levels in Glp1r$^{-/-}$ mice were due to enhanced insulin signaling (Fig. 5). In chow-fed mice, disruption of Glp1r expression did not increase levels of phosphorylated Akt, total Akt, or Akt activation in muscle (Fig. 5, A–C). In HF-fed Glp1r$^{-/-}$ mice, however, levels of phosphorylated Akt were higher compared with Glp1r$^{+/+}$ mice, whereas total Akt levels were lower (Fig. 5, A and B). Thus, muscle Akt activation was enhanced in HF-fed Glp1r$^{-/-}$ mice (Fig. 5C). Furthermore, HF feeding impaired muscle Akt activation in Glp1r$^{+/+}$ mice but not in Glp1r$^{-/-}$ mice (Fig. 5C). These results show that whereas disruption of Glp1r expression enhances insulin-stimulated muscle Rg regardless of diet, this is only associated with enhanced insulin signaling in HF-fed mice.

To determine whether differences in the ability of insulin to suppress endoRa were associated with effects on insulin signaling, activation of hepatic Akt was also assessed. As seen in Fig. 5, D and E, hepatic Akt activation was not different between chow-fed Glp1r$^{+/+}$ and Glp1r$^{-/-}$ mice. However, absolute levels of phosphorylated and total Akt were lower in Glp1r$^{-/-}$ mice. In HF-fed mice, phosphorylated Akt levels were significantly higher in Glp1r$^{-/-}$ mice, whereas total Akt levels were lower (Fig. 5B). The end result was that hepatic Akt activation was significantly enhanced in HF-fed Glp1r$^{-/-}$ mice. Furthermore, although HF feeding impaired hepatic insulin signaling in Glp1r$^{+/+}$ mice, this impairment did not occur in Glp1r$^{-/-}$ mice (Fig. 5F).

**HF-fed Glp1r$^{-/-}$ mice exhibit decreased muscle triglyceride accumulation and increased AMPK activation**

Tissue lipid accumulation negatively affects insulin action. Muscle triglyceride levels were measured to assess whether enhanced muscle insulin action in Glp1r$^{-/-}$ mice correlated with decreased triglyceride levels. There was no difference in muscle triglycerides between genotypes in chow-fed mice. However, HF-fed Glp1r$^{-/-}$ mice exhibited lower triglyceride levels compared with their Glp1r$^{+/+}$ counterparts (Fig. 6A). The activation of AMPK, assessed as the ratio of phosphorylated to total AMPK, was measured to determine whether decreased muscle triglyceride levels were associated with increased oxidation capacity. HF-fed Glp1r$^{-/-}$ mice exhibited increased activation of AMPK (Fig. 6, B–D) compared with their Glp1r$^{+/+}$ counterparts. There was a slight, although not significant, increase in the levels of activated AMPK in skeletal muscle of chow-fed Glp1r$^{-/-}$ mice.

**Hepatic triglyceride levels and SREBP-1 expression are decreased in HF-fed Glp1r$^{-/-}$ mice**

Liver triglyceride accumulation was measured to determine whether enhanced hepatic insulin action in HF-fed Glp1r$^{-/-}$ mice correlated with decreased hepatic triglyceride
levels. There was no difference in hepatic triglyceride levels between genotypes in chow-fed mice (Fig. 6E). HF-fed Glp1r+/H11002/H11002 mice showed significantly decreased triglyceride accumulation compared with HF-fed Glp1r+/H11001/H11001 mice (Fig. 6E). Although HF feeding increased levels of nuclear SREBP-1 in Glp1r+/H11001/H11001 mice, this increase was not observed in HF-fed Glp1r+/H11002/H11002 mice (Fig. 6, F and G).

Discussion

A role for Glp1 in the regulation of glucose production and use independent of its effects to stimulate insulin secretion has been suggested by some clinical studies (27–34) but disputed by other clinical studies (35–40). Our laboratory has previously demonstrated that disruption of the Glp1r, either in Glp1r+/−/− (18) or DIRKO (9) mice, impairs hepatic insulin action but reciprocally enhances muscle insulin action under controlled hyperinsulinemic-euglycemic conditions. The present studies further support a role for the Glp1r in the regulation of insulin action in the context of HF diet-induced insulin resistance. We show that the beneficial effect of disrupting Glp1r expression on muscle insulin action is sufficient to reduce the insulin resistance associated with HF feeding. A key finding in this study was that improved muscle insulin action in the HF-fed Glp1r+/H11002/H11002 mice was observed independent of any effects on body weight and fat mass. We have previously reported impaired hepatic insulin action in chow-fed Glp1r+/−/− mice of both sexes (18). In the present studies using male mice, there was a tendency for the suppression of endoRα by insulin to be impaired (P > 0.05) in chow-fed Glp1r+/−/− mice. Surprisingly, rather than exacerbating hepatic insulin resistance, disruption of Glp1r expression resulted in improved suppression of endoRα in HF-fed mice.

Contrasting the findings from our laboratory, Hansotia et al. (41) have previously shown that male Glp1r+/−/− mice on a C57BL/6 background are significantly protected from HF diet-induced weight gain. However, those studies used a HF diet with significantly lower fat content than the diet used in the current studies (45 vs. 60 kcal/g, respectively). Furthermore, the mice used in the studies of Hansotia et al. (41) were placed on the HF diet at 9 wk of age, which is beyond the exponential growth phase in mice. This is in contrast to the present studies, in which mice were placed on a HF diet at 3 wk of age. We can therefore not exclude the possibility that placing mice on a very high
fat diet at a time point early in the exponential growth phase, as was done in the present studies, prevents the divergence in weight gain observed by Hansotia et al. (41). Nevertheless, the present studies circumvent the confounding effects of differences in body weight by assessing insulin action in weight-matched male Glp1r+/−/− and Glp1r+/−/− mice.

In support of our previous studies (18), enhanced insulin-stimulated MGU in chow-fed Glp1r+/−/− mice was not due to an effect on insulin signaling because muscle Akt activation was not increased. Recently Cabou et al. (42) reported that inhibition of central Glp1rs via icv infusion of exendin 9–39, a Glp1r antagonist, enhanced femoral arterial blood flow during a hyperinsulinemic-hyperglycemic clamp. Increased blood flow to the muscle is speculated to enhance MGU via greater delivery of insulin and glucose to the tissue (43–45). Indeed, we have previously demonstrated enhanced insulin-stimulated MGU in mice treated with the vasodilator sildenafil independent of muscle phosphatidylinositol 3-kinase or Akt activation (12). However, a role for the Glp1r to regulate MGU is not completely independent of an effect on insulin signaling because muscle Akt activation was higher in HF-fed Glp1r+/−/− mice compared with Glp1r+/−/+ mice. Inhibition of central Glp1r action has been shown to increase expression of endothelial nitric oxide synthase in skeletal muscle (19), which would be expected to have a positive effect on muscle blood flow. It is conceivable that through this mechanism the Glp1r regulates insulin-stimulated MGU via modulation of muscle blood flow. Activation of muscle AMPK is also increased in Glp1r+/−/− mice. This would be predicted to enhance muscle glucose uptake independent of insulin signaling (46). Furthermore, the increase in activated AMPK likely contributes to the lower muscle triglyceride levels in HF-fed Glp1r+/−/− mice, secondarily enhancing insulin action. We have previously observed a significant increase in muscle AMPK activation in Glp1r+/−/− mice in response to exercise. Disruption of Glp1r expression, in both DIRKO mice (9, 41) and Glp1r−/− mice (41), increases locomotor activity. It is reasonable to suggest that increased activity in

**FIG. 5.** Immunoblots for insulin signaling proteins after insulin clamp experiments. Representative immunoblots from gastrocnemius muscle (A) and liver (D) extracts are shown. Quantification of protein content for phosphorylated and total Akt (B and E) and Akt activation (C and F) is shown for chow-fed Glp1r+/−/− (black bars), chow-fed Glp1r+/−/− (white bars), HF-fed Glp1r+/−/− (black bars), and HF-fed Glp1r+/−/− (diamond pattern bars) mice. GAPDH was used as a loading control. Data are shown as mean ± sem for 8–10 mice/genotype and diet. *P < 0.05 vs. Glp1r+/−/+, same diet; †P < 0.05 vs. Chow, same genotype.

**FIG. 6.** Gastrocnemius muscle (A) and liver (E) triglyceride levels in chow-fed Glp1r+/−/− (black bars), chow-fed Glp1r−/− (white bars), HF-fed Glp1r+/−/− (striped bars) and HF-fed Glp1r+/−/− (diamond pattern bars) mice after insulin clamps. Representative immunoblots (B) and quantification of protein content (C) for phosphorylated AMPK(Thr172), total AMPK and loading control (GAPDH) from superficial vastus lateralis muscle in 5 h-fasted mice. Muscle AMPK activation (D). Representative immunoblots (F) and quantification of protein content (G) for nuclear SREBP-1 and loading control (YY1) from nuclear extracts isolated from livers after insulin clamps. Data are shown as mean ± sem for 4–10 mice/genotype and diet. *P < 0.05 vs. Glp1r+/−/+, same diet; †P < 0.05 vs. Chow, same genotype.
Glp1r<sup>−/−</sup> mice results in enhanced activation of muscle AMPK and increased oxidation of fat. This phenotype resembling exercise training would be predicted to enhance muscle insulin action. We previously showed that Glp1r<sup>−/−</sup> mice exhibit impaired hepatic insulin action (18). It was therefore hypothesized that disruption of Glp1r expression would further exacerbate HF diet-induced hepatic insulin resistance. Instead, the ability of insulin to suppress endoR<sub>4</sub> was improved in HF-fed Glp1r<sup>−/−</sup> mice. This is likely due to decreased accumulation of hepatic triglycerides in HF-fed Glp1r<sup>−/−</sup> mice. Because intracellular accumulation of lipids correlates with tissue insulin resistance, a decrease in hepatic lipid accumulation in Glp1r<sup>−/−</sup> mice could have a positive effect on insulin action. Indeed, decreased levels of phosphorylated Akt in the livers of chow-fed Glp1r<sup>−/−</sup> and HF-fed Glp1r<sup>+/+</sup> mice, both exhibiting hepatic insulin resistance, are normalized in HF-fed Glp1r<sup>−/−</sup> mice. Thus, reduced lipid accumulation may overcome any deleterious effect of disrupting Glp1r expression on hepatic insulin action in HF-fed mice. Although suppression of endoR<sub>4</sub> by insulin was enhanced in HF-fed Glp1r<sup>−/−</sup> mice, these mice did exhibit some markers of impaired hepatic insulin action. Similar to phenotypes observed in chow-fed Glp1r<sup>−/−</sup> mice, hepatic glycogen levels and total Akt expression were lower in HF-fed Glp1r<sup>−/−</sup> mice at the end of the insulin clamp. A direct role for the Glp1r to regulate hepatic Akt expression is not clear because the Glp1r is reportedly not expressed in hepatocytes. However, the effect on glycogen levels suggests that suppression of glycogenolysis and/or stimulation of hepatic glucose uptake are impaired in Glp1r<sup>−/−</sup> mice. In support of the latter, Zheng et al. (47) have shown that the Glp1r agonist exenatide stimulates hepatic uptake of exogenous glucose. HF-fed Glp1r<sup>−/−</sup> also did not exhibit an increase in activation of hepatic SREBP-1. One of the paradoxes of insulin resistance is that, whereas the liver becomes resistant to the actions of insulin to suppress glucose production, it remains sensitive to insulin-stimulated lipogenesis via activation of SREBP-1 (48). HF-fed Glp1r<sup>−/−</sup> mice demonstrate the opposite phenotype. These mice are more sensitive than their Glp1r<sup>+/+</sup> counterparts to suppression of glucose production by insulin but less sensitive to the stimulation of lipogenesis by insulin via SREBP-1. Reduced hepatic lipogenesis would be predicted to decrease export of very low-density lipoprotein to tissues such as the muscle. This would contribute to the decreased muscle triglyceride levels and enhanced muscle insulin action in HF-fed Glp1r<sup>−/−</sup> mice.

The contributions of glucagon to the observed phenotypes in Glp1r<sup>−/−</sup> mice cannot be excluded. Because activation of the Glp1r suppresses glucagon secretion (5, 6, 8), it is reasonable to assume that Glp1r<sup>−/−</sup> mice would exhibit increased glucagon levels. This could explain the impaired suppression of endoR<sub>4</sub> in chow-fed Glp1r<sup>−/−</sup> mice during the insulin clamps. We did not observe significant differences in glucagon levels between genotypes within each diet group. This is supported by previous studies showing normal fasting glucagon levels, as well as normal suppression of glucagon by oral glucose loading, in Glp1r<sup>−/−</sup> mice (49–51). These measurements of glucagon levels were made from arterial or cardiac blood samples. Because glucagon clearance occurs in the liver, measurement of glucagon levels in the portal circulation would more accurately determine whether differences exist in the secretion of this hormone. We can therefore not exclude the possibility that glucagon levels are increased in the portal circulation of Glp1r<sup>−/−</sup> mice.

Recent evidence supports a key role for central, particularly hypothalamic, Glp1r action in the regulation of muscle and hepatic insulin action. Knauf et al. (52) showed increased muscle glycogen accumulation and decreased hepatic glycogen levels in mice receiving icv infusions of the Glp1r antagonist exendin 9–39 during a hyperinsulinemic-hyperglycemic clamp. In rats, infusion of Glp1 directly into the arcuate nucleus enhances the suppression of endoR<sub>4</sub> and the stimulation of R<sub>4</sub> during an insulin clamp (53). Recently Knauf et al. (19) showed that a 4-wk icv infusion of exendin 9–39 in mice fed a carbohydrate-free HF diet resulted in a normalization of fasting hyperinsulinemia and hyperglycemia, which is in agreement with our present studies, as well as improved intra-peritoneal glucose tolerance. Food intake was increased, but total weight and fat mass were not affected due to an increase in energy expenditure. This increase in energy expenditure was associated with increased locomotor activity and enhanced oxidative capacity in skeletal muscle (19). Improvements in muscle insulin action, assessed via a hyperinsulinemic-hyperglycemic clamp, were also suggested. However, the omission of standard data for insulin clamps such as insulin levels, glucose levels, and GIRs, makes interpretation of those clamp results impossible. Further complicating interpretation of the results obtained by Knauf et al. (19) is that a carbohydrate-free HF diet was used. The physiological irrelevance of using a carbohydrate-free diet to study the role of the Glp1r to regulate carbohydrate flux is clear. Nevertheless, in agreement with our present studies, blocking central Glp1rs has no effect on body weight or composition in HF-fed mice. This further supports a role for the Glp1r to regulate glucose production and use in insulin-resistant states independent of effects on body weight.

It is well established that Glp1 regulates hepatic glucose production and muscle glucose uptake via its in-
sulinotropic and glucagonostatic actions. The present studies extend the glucoregulatory properties of Glp1 by showing that, under conditions of insulin-stimulated glucose flux, the Glp1r regulates glucose production and use independent of its ability to stimulate insulin secretion. Our previous and current findings in chow-fed mice suggest that Glp1r activation enhances the ability of insulin to suppress hepatic glucose production and stimulates hepatic glucose disposal at the expense of insulin-stimulated muscle glucose uptake. This mechanism would ensure the replenishment of hepatic glycogen stores after a meal and the maintenance of glucose homeostasis during the postabsorptive period. Our studies in HF-fed mice propose a role for the Gp1r in the regulation of the balance between fat and glucose metabolism. HF-fed Glp1r−/− mice exhibit decreased lipid accumulation in the liver and skeletal muscle, thus enhancing insulin action in these tissues. Similar findings in studies using targeted Glp1r activation and inhibition in the brain further suggest that central Glp1r signaling can also regulate hepatic and muscle insulin action. Taken together, our studies extend the role of Glp1 in the regulation of metabolic homeostasis to include both insulin secretion dependent and independent mechanisms.

Acknowledgments

We thank Dr. Owen McGuinness, Carlo Malabanan, and Tasneem Ansari (Vanderbilt Mouse Metabolic Phenotyping Center Metabolic Pathophysiology Core) for body composition analysis.

Address all correspondence and requests for reprints to: Julio E. Ayala, Ph.D., Sanford-Burnham Medical Research Institute at Lake Nona, 6400 Sanger Road, Orlando, Florida 32827. E-mail: jayala@sanfordburnham.org.

This work was supported by Grant 1-09-JF-03 from the American Diabetes Association (to J.E.A.), Grants R01 DK-54902 (to D.H.W.) and U24 DK-59637 (to the Vanderbilt Mouse Metabolic Phenotyping Center) from the National Institutes of Health, and Grant 1-2006-796 from the Juvenile Diabetes Research Foundation (to D.J.D.).

Disclosure Summary: D.J.D. has served as an adviser or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals Inc., Arisaph Pharmaceuticals Inc., Eli Lilly Inc., Glaxo Smith Kline, Genmark Pharmaceuticals, Hoffmann-La Roche Inc., Isis Pharmaceuticals Inc., Merck Research Laboratories, Metabolex Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Pharmakin Inc., and Transition Pharmaceuticals Inc. Neither D.J.D. nor his family members hold stock directly or indirectly in any of these companies. The other authors have nothing to declare.

References

through body composition changes. Biochem Biophys Res Commun 364:175–180


